Safety and immunogenicity from a Phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine

Emergence of severe acute respiratory syndrome (SARS) from the winter of 2002 to the spring of 2003 has caused a serious threat to public health. To evaluate the safety and immunogenicity of the inactivated SARS coronavirus (SARS-CoV) vaccine, 36 subjects received two doses of 16 SARS-CoV units (SU)...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2007-01, Vol.12 (7), p.1107-1113
Main Authors: LIN, Jiang-Tao, ZHANG, Jian-San, YAN LIU, SUN, Rui-Hua, XU WANG, YU, Dong-Zheng, RONG HAI, QIANG GAO, YE NING, WANG, Hong-Xia, LI, Ma-Chao, BIAO KAN, NAN SU, DONG, Guan-Mu, QI AN, WANG, Ying-Qun, JUN HAN, CHUAN QIN, YIN, Wei-Dong, DONG, Xiao-Ping, XU, Jian-Guo, NAN WANG, CHEN, Jiang-Ting, XIN CHEN, LIU, Yu-Xuan, HONG GAO, JIA, Yu-Ping
Format: Article
Language:English
Subjects:
Adult
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antibodies, Viral - biosynthesis
Antibodies, Viral - immunology
Antiviral agents
Biological and medical sciences
Double-Blind Method
Female
Human viral diseases
Humans
Infectious diseases
Male
Medical sciences
Neutralization Tests
Pharmacology. Drug treatments
SARS Virus - immunology
Severe Acute Respiratory Syndrome - immunology
Severe Acute Respiratory Syndrome - therapy
Severe Acute Respiratory Syndrome - virology
Vaccination
Vaccines, Inactivated - adverse effects
Vaccines, Inactivated - immunology
Viral diseases
Viral diseases of the respiratory system and ent viral diseases
Viral Vaccines - adverse effects
Viral Vaccines - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Emergence of severe acute respiratory syndrome (SARS) from the winter of 2002 to the spring of 2003 has caused a serious threat to public health. To evaluate the safety and immunogenicity of the inactivated SARS coronavirus (SARS-CoV) vaccine, 36 subjects received two doses of 16 SARS-CoV units (SU) or 32 SU inactivated SARS-CoV vaccine, or placebo control. On day 42, the seroconversion reached 100% for both vaccine groups. On day 56, 100% of participants in the group receiving 16 SU and 91.1% in the group receiving 32 SU had seroconverted. The geometric mean titre of neutralizing antibody peaked 2 weeks after the second vaccination, but decreased 4 weeks later. The inactivated vaccine was safe and well tolerated and can elicit SARS-CoV-specific neutralizing antibodies.
ISSN:1359-6535
2040-2058
DOI:10.1177/135965350701200702